Latest news with #BenEdwards
Tom's Guide
a day ago
- Entertainment
- Tom's Guide
Prime Video drops first look at new action-thriller show with Chris Pratt — and it's a prequel to 'The Terminal List'
Prime Video is diving back into the gritty world of military thrillers with 'The Terminal List: Dark Wolf,' a new prequel series set to premiere on August 27, 2025. Co-created by bestselling author Jack Carr (whose novel inspired the original series) and returning showrunner David DiGilio, 'Dark Wolf' sets the stage for everything that came before 'The Terminal List,' and it could be just as intense judging by the premise and newly released images. This time, the spotlight shifts to Ben Edwards (Taylor Kitsch), in an origin story that traces his path from Navy SEAL to the covert world of CIA Special Operations. The series will lean into the espionage side of the action by showing a deeper, darker look at the human toll of warfare and what it really means to operate in the shadows. And yes, Chris Pratt is reprising his role as James Reece. The first-look images recently dropped thanks to Prime Video, and while they don't give much away, they do introduce us to the main group of characters, along with a few tense action shots. If you enjoyed the original show, and have been waiting for more, here's everything to know about 'The Terminal List: Dark Wolf.' Along with the first-look images, Prime Video has also shared more plot details about what to expect when 'The Terminal List: Dark Wolf' premieres later in August. Of course, we'll get a trailer closer to the release date, but for now, here's the official synopsis: Get instant access to breaking news, the hottest reviews, great deals and helpful tips. 'Co-created by The New York Times bestselling author of The Terminal List, Jack Carr, and Season One creator-showrunner David DiGilio, The Terminal List: Dark Wolf is a prequel series with an origin story that follows Ben Edwards (Taylor Kitsch) throughout his journey from the Navy SEALs to the clandestine side of CIA Special Operations. 'The series is an espionage thriller that explores the darker side of warfare and the human cost that comes with it. It also features Chris Pratt reprising his role as James Reece.' Like the first season of 'The Terminal List,' 'Dark Wolf' places a strong emphasis on authenticity. From the way military missions and intelligence work are portrayed to the emotional weight carried by those who serve, the series aims to keep things grounded and true to life. Behind the scenes, real military veterans have had a hand in shaping the story — as writers, actors, advisors, and executive producers — helping to ensure the show captures the mindset, camaraderie, and moral gray areas that come with life in Special Operations. At the end of 'The Terminal List,' James Reece uncovers a deadly conspiracy that links his team's ambush and his family's murder to a failed government drug trial. One by one, he eliminates those responsible — including close friend Ben Edwards, who betrayed him for money. When speaking with USA Today, Kitsch said: 'This is the origin story. This is the story that gets us to that point. There was so much heat around Edwards with that twist and all these questions about how. You're going to learn a heck of a lot more about who Ben really is and these twists and turns that led to that decision.' The supporting cast for the series features a strong lineup, including Tom Hopper as Raife Hastings, Robert Wisdom as Jed Haverford, and Luke Hemsworth as Jules Landry. Other cast members include Dar Salim as Mohammed Farooq, Rona-Lee Shimon as Eliza Perash, Shiraz Tzarfati as Tal Varon, and Jared Shaw as Ernest 'Boozer' Vickers, with several more names rounding out the ensemble. This show also brings together an impressive team behind the scenes, with Kitsch and Pratt both serving as executive producers. The series is also executive produced by returning showrunner David DiGilio, original author Jack Carr, and director Antoine Fuqua alongside Kat Samick via Hill District Media. 'The Terminal List: Dark Wolf' is set to debut with its first three episodes on Wednesday, August 27, 2025, streaming exclusively on Prime Video across more than 240 countries and territories. After the premiere, new episodes will roll out each week, with the season wrapping up on Wednesday, September 24. With its talented cast, real-world expertise behind the camera, and a deeper dive into fan-favorite characters, 'The Terminal List: Dark Wolf' is shaping up to be an exciting summer release. In the meantime, see what's new on Prime Video in June 2025.
Yahoo
6 days ago
- Entertainment
- Yahoo
Look: 'Terminal List: Dark Wolf' gets photos, August premiere date
May 29 (UPI) -- Prime Video is teasing the Terminal List prequel series, which premieres with three episodes Aug. 27. "The Terminal List: Dark Wolf is a prequel series with an origin story that follows Ben Edwards (Taylor Kitsch) throughout his journey from the Navy SEALs to the clandestine side of CIA Special Operations," an official synopsis reads. The streamer also released first-look images Thursday. A pair of photos show Ben and James Reece, who is portrayed by Chris Pratt, at work. The series also stars Tom Hopper, Robert Wisdom, Luke Hemsworth, Dar Salim, Rona-Lee Shimon, Shiraz Tzarfati and Jared Shaw. Dark Wolf is co-created by Jack Carr, who authored the Terminal List book series, and the Terminal List television series creator and showrunner David DiGilio. The original Terminal List premiered on Prime Video in 2022 and will return for a second season.
UPI
6 days ago
- Entertainment
- UPI
Look: 'Terminal List: Dark Wolf' gets photos, August premiere date
1 of 5 | "The Terminal List: Dark Wolf" arrives on Prime Video Aug. 27. Photo by Justin Lubin/Prime Video May 29 (UPI) -- Prime Video is teasing the Terminal List prequel series, which premieres with three episodes Aug. 27. "The Terminal List: Dark Wolf is a prequel series with an origin story that follows Ben Edwards (Taylor Kitsch) throughout his journey from the Navy SEALs to the clandestine side of CIA Special Operations," an official synopsis reads. The streamer also released first-look images Thursday. A pair of photos show Ben and James Reece, who is portrayed by Chris Pratt, at work. The series also stars Tom Hopper, Robert Wisdom, Luke Hemsworth, Dar Salim, Rona-Lee Shimon, Shiraz Tzarfati and Jared Shaw. Witness the untold story of Ben Edwards - starting August 27. #TheTerminalList: #DarkWolf The Terminal List (@TerminalListPV) May 28, 2025 Dark Wolf is co-created by Jack Carr, who authored the Terminal List book series, and the Terminal List television series creator and showrunner David DiGilio. The original Terminal List premiered on Prime Video in 2022 and will return for a second season. Marvel stars walk the red carpet Iron Man star Robert Downey Jr. (R), and his wife, Susan Downey, attend the premiere of "Avengers: Endgame" in Los Angeles on April 22, 2019. Downey, in 2024, announced that he will be returning to the Marvel Cinematic Universe as the villainous Dr. Doom. Photo by Jim Ruymen/UPI | License Photo
Yahoo
26-05-2025
- Business
- Yahoo
Australia Delivers Certainty for US Biotechs in 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, and R&D Rebates
ADELAIDE, Australia, May 26, 2025 (GLOBE NEWSWIRE) -- As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase clinical trials. With its globally accepted regulatory framework, accelerated timelines, and 43.5% R&D rebate, Australia offers a compelling advantage — and Avance Clinical, Australia's leading early-phase specialist CRO, is delivering the GlobalReady solution to help biotechs de-risk, conserve capital and accelerate their programs. 'In today's capital-constrained biotech environment, sponsors need solutions that deliver speed, predictability, quality, and capital efficiency,' said Ben Edwards, Chief Operating Officer at Avance Clinical. 'Australia is a smart strategic choice — it allows biotechs to start faster, control costs, reduce burn rate, and generate FDA-accepted data without the delays and complexity of the US IND process in a Phase I setting.' Through its GlobalReady program, Avance Clinical enables biotech sponsors to rapidly initiate early phase trials in Australia — often within 5 to 6 weeks — without the need for an open IND. The company's deep regulatory and scientific expertise ensures that data generated under the Australian Therapeutic Goods Administration (TGA) framework is accepted by the FDA and other major regulatory agencies worldwide. In addition to regulatory speed and data quality, Australia offers a unique fiscal advantage with its 43.5% R&D tax rebate, significantly reducing early clinical trial costs — a major incentive for venture-backed biotech companies managing limited runway. As part of its GlobalReady model, Avance Clinical also facilitates expansion into Asia, where its newly signed partnerships with leading Taiwanese and South Korean clinical sites offer biotechs access to large, treatment-naïve patient populations — essential for fast Phase II and III recruitment. For later-phase trials, Avance Clinical also provides a seamless expansion to its US-based operational and regulatory teams, ensuring continuity, quality oversight, and alignment with sponsor expectations throughout the development lifecycle. "Our model is built specifically for biotechs — agile, science-driven, capital efficient and globally integrated," said Edwards. "From Australia to Asia to the US, we provide a single CRO partner to guide clinical programs from first-in-human to regulatory submission." Avance Clinical will be showcasing its GlobalReady capabilities at two major US conferences: the 2025 ASCO Annual Meeting in Chicago, 30 May – 3 June, and BIO International 2025 in Boston, 16 – 19 June. To schedule a meeting with the team, please visit About Avance Clinical Avance Clinical is a leading full-service CRO offering biotech companies faster, more flexible, and higher-quality clinical trial services. Headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe. With over 30 years of experience and expertise in more than 250 indications, the company specializes in early to late-phase clinical trials, providing comprehensive support from pre-clinical consulting through to Phase I-II studies. Discover Avance Clinical's Australian Advantage and Asia Advantage Get into clinic faster with Avance Clinical's ClinicReady service Learn about Avance Clinical's GlobalReady model for biotechs Speak with our scientific experts about your upcoming study Book a meeting or request a proposal For media enquiries, email media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Australia Delivers Certainty for US Biotechs in 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, and R&D Rebates
ADELAIDE, Australia, May 26, 2025 (GLOBE NEWSWIRE) -- As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase clinical trials. With its globally accepted regulatory framework, accelerated timelines, and 43.5% R&D rebate, Australia offers a compelling advantage — and Avance Clinical, Australia's leading early-phase specialist CRO, is delivering the GlobalReady solution to help biotechs de-risk, conserve capital and accelerate their programs. 'In today's capital-constrained biotech environment, sponsors need solutions that deliver speed, predictability, quality, and capital efficiency,' said Ben Edwards, Chief Operating Officer at Avance Clinical. 'Australia is a smart strategic choice — it allows biotechs to start faster, control costs, reduce burn rate, and generate FDA-accepted data without the delays and complexity of the US IND process in a Phase I setting.' Through its GlobalReady program, Avance Clinical enables biotech sponsors to rapidly initiate early phase trials in Australia — often within 5 to 6 weeks — without the need for an open IND. The company's deep regulatory and scientific expertise ensures that data generated under the Australian Therapeutic Goods Administration (TGA) framework is accepted by the FDA and other major regulatory agencies worldwide. In addition to regulatory speed and data quality, Australia offers a unique fiscal advantage with its 43.5% R&D tax rebate, significantly reducing early clinical trial costs — a major incentive for venture-backed biotech companies managing limited runway. As part of its GlobalReady model, Avance Clinical also facilitates expansion into Asia, where its newly signed partnerships with leading Taiwanese and South Korean clinical sites offer biotechs access to large, treatment-naïve patient populations — essential for fast Phase II and III recruitment. For later-phase trials, Avance Clinical also provides a seamless expansion to its US-based operational and regulatory teams, ensuring continuity, quality oversight, and alignment with sponsor expectations throughout the development lifecycle. "Our model is built specifically for biotechs — agile, science-driven, capital efficient and globally integrated," said Edwards. "From Australia to Asia to the US, we provide a single CRO partner to guide clinical programs from first-in-human to regulatory submission." Avance Clinical will be showcasing its GlobalReady capabilities at two major US conferences: the 2025 ASCO Annual Meeting in Chicago, 30 May – 3 June, and BIO International 2025 in Boston, 16 – 19 June. To schedule a meeting with the team, please visit About Avance Clinical Avance Clinical is a leading full-service CRO offering biotech companies faster, more flexible, and higher-quality clinical trial services. Headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe. With over 30 years of experience and expertise in more than 250 indications, the company specializes in early to late-phase clinical trials, providing comprehensive support from pre-clinical consulting through to Phase I-II studies. Discover Avance Clinical's Australian Advantage and Asia Advantage Get into clinic faster with Avance Clinical's ClinicReady service Learn about Avance Clinical's GlobalReady model for biotechs Speak with our scientific experts about your upcoming study Book a meeting or request a proposal For media enquiries, email media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
